Author Archives: admin


What’s On The Ballot? A Summary Of The 12 State Propositions For November 2020 Election – KHTS Radio

When Santa Clarita residents cast their ballots in November during the 2020 election, they will have the opportunity to vote on a dozen state propositions ranging from cash bail to affirmative action.

At the beginning of July, the Office of the California Secretary of State posted the 12 statewide ballot measures that had qualified for the 2020 election on Nov. 3.

Out of the dozen state propositions set to be voted on in November, eight were placed on the ballot by citizens and special interests, while four were put on by state legislators.

With issues ranging from lifting the decades-old ban on affirmative action to the fate of the cash bail system in California, here are the 12 state propositions Santa Clarita residents are set to vote on in November.

Bonds

Only one state bond measure made it onto the ballot this year, with this one going towards the funding of stem cell research.

Prop 14: Authorize Bonds to Continue Funding Stem Cell and Other Medical Research

This proposition would authorize $5.5 billion in state general obligation bonds to fund grants from the California Institute of Regenerative Medicine to educational, non-profit, and private entities for three things:

As part of this, $1.5 billion would also go towards funding research and therapy for Alzheimers, Parkinsons, stroke, epilepsy and other brain and central nervous system diseases and conditions, according to the propositions text.

See Related: COC Measure E Committee, COC Foundation Fined $14,500 For Campaign Violations

The California Institute for Regenerative Medicine was initially created after California voters passed Proposition 71 in 2004, which allowed the state to borrow roughly $3 billion to create the institute.

While payments on the bond would be postponed for an initial five years, money from the states General Fund would be used to pay back the estimated $7.8 billion cost of the bond (principal of $5.5 billion, interest of $2.3 billion).

Housing/Real Estate

There are three measures on the 2020 ballot that pertain to housing and real estate, including the controversial issues of rent control and the split roll tax.

Prop 15: Increases Funding for Public Schools, Community Colleges, and Local Government Services by Changing Tax Assessment of Commercial and Industrial Property

More commonly known as the split roll tax, this proposition would require certain commercial and industrial properties to be taxed based on their current market value, as opposed to the market value when the property was originally purchased.

Proposition 15 would overturn a portion of Proposition 13, a measure passed by California voters in 1978 that capped property taxes from increasing as the market value of a piece of property increased.

Residential and agricultural properties would be exempt from the measure, as well as commercial and industrial properties with a combined value of $3 million or less.

State officials say that an estimated $7.5 billion to $12 billion would be generated each year, the majority of which would go towards public schools and local governments.

Prop 19: ACA 11: The Home Protection for Seniors, Severely Disabled, Families, and Victims of Wildfire or Natural Disasters Act

This measure would allow eligible homeowners to transfer their tax assessments anywhere within the state and allow tax assessments to be transferred to a more expensive home with an upward adjustment

Additionally, it would increase the number of times that a person over the age of 55 or an individual with severe disabilities can transfer their tax assessments from one to three.

The measure also requires that any homes that a person inherits and does not use as a principal residence to be reassessed using the market value at the time of the transfer.

The majority of funds raised by this measure would go towards combating wildfires, as well as local counties.

Prop 21: Expands Local Governments Authority to Enact Rent Control on Residential Property

This proposition would amend state law to allow local governments to establish rent control on residential properties over 15 years old.

State legislators had previously passed a law in 2019 that set a seven percent ceiling on how much landlords can raise their rents each year.

The measure exempts single-family homes owned by landlords with no more than two properties.

If the measure is passed, state officials estimated a potential reduction in state and local revenues of tens of millions of dollars per year in the long term, depending on the actions that local communities take.

Civil Rights

The largest section of the 2020 ballot is dedicated to various civil rights issues ranging from affirmative action to lifting some voting restrictions.

Prop 16: ACA 5: Government Preferences

Proposition 16 would repeal an amendment to the state constitution that bans the practice of affirmative action within state institutions.

Passed in 1996, Proposition 209 amended the California Constitution to prohibit any public agency from discriminating against, or granting preferential treatment to, any individual or group on the basis of race, sex, color, ethnicity or national origin.

See Related: Senator Scott Wilk Votes To Put Repeal Of State Affirmative Action Ban On November Ballot

Republican State Senator Scott Willk, who represents Santa Clarita Valley as part of the 21st Senate District, crossed the aisle and voted to put this measure on the ballot, stating at the time that with the conversations many citizens have been having around their dinner tables the past few weeks, it is reasonable to let voters revisit this issue.

The measure was introduced by Democratic Assemblywoman Shirley Weber of San Diego.

Prop 17: ACA 6: Elections: Disqualification of Electors

If passed, Proposition 17 would allow individuals who were out of prison on parole for a felony conviction to vote.

Under the California Constitution, felons are disqualified from voting until both their imprisonment and parole are completed.

Proposition 17 would amend the state constitution to allow felons out on parole to vote, restoring the right to vote to an estimated 40,000 Californians.

The measure was introduced by Democratic Assemblyman Kevin McCarty of Sacramento.

Prop 18: ACA 4: Elections: Voting Age

This measure would allow 17-year-olds to vote in primary and special elections, provided that they will be 18 at the time of the subsequent general election.

This is the first time that such a measure has made it onto the ballot, despite lawmakers pushing similar efforts several times in the past.Similar measures have already been approved in at least 18 other states, as well as Washington D.C.

The proposition was introduced by Democratic Assemblyman Kevin Mullin of San Mateo

Prop 24: Amends Consumer Privacy Laws

Proposition 24 would expand consumer data privacy laws in the state of California, which are already considered the strongest in the nation.

Under this measure, consumers would be allowed to:

In addition to prohibiting businesses from retaining personal information for longer than reasonably necessary, the measure also triples maximum penalties for certain violations concerning consumers under the age of 16.

The proposition would also establish the California Privacy Protection Agency in order to enforce and implement consumer privacy laws, and impose administrative fines.

Criminal Justice

Two measures pertaining to criminal justice are on the ballot this year, with one addressing the future of the cash bail system within the state of California.

Prop 20: Restricts Parole for Non-Violent Offenders. Authorizes Felony Sentences For Certain Offenses Currently Treated Only as Misdemeanors

If passed, Proposition 20 would add crimes to the list of violent felonies for which early parole is restricted, allow prosecutors to charge certain misdemeanor crimes with felony charges, and require people convicted of specified misdemeanors to submit to collection of DNA samples for a state database.

Under the measure, those who are convicted of domestic violence, as well as other crimes that are currently categorized as nonviolent, would no longer be considered for early parole.

See Related: Dozens Of Residents Protest Against Human Trafficking In Valencia

Additionally, the passage of the proposition would make specific types of theft and fraud crimes such as firearm theft, vehicle theft, and unlawful use of a credit card chargeable as misdemeanors or felonies, rather than just misdemeanors.

The ballot initiative also establishes two new types of crimes in state code (serial crime and organized retail crime), which could be charged as either a misdemeanor or a felony.

Prop 25: Referendum to Overturn a 2018 Law That Replaced Money Bail System with a System Based on Public Safety Risk

This measure looks to uphold contested legislation that replaces Californias cash bail system with risk assessments for detained suspects awaiting trials.

In 2018, state legislators passed Senate Bill 10, which eliminated the cash bail system, and instead gave judges the role in determining whether or not an arrested individual should be held in jail or not leading up to their trial based on the risk that they pose to others or themself.

The law also restricts pretrial detentions for many misdemeanor charges.

Voting yes on Proposition 25 would uphold the 2018 law, while voting no would overturn it and bring back cash bail to California.

Labor

The final two ballot initiatives on this years ballot involve labor regulations, including a vote on whether or not to reclassify ride-share drivers as independent contractors.

Prop 22: Changes Employment Classification Rules for App-Based Transportation and Delivery Drivers

Proposition 22 would reclassify drivers for ride-share apps or food delivery services as independent contractors, essentially overturning a significant portion of Assembly Bill 5 (AB 5), which was passed in September of 2019.

This would exempt companies such as Uber and Lyft from standard wage and hour restrictions.

In exchange, companies with independent-contractor drivers would be required to provide specified alternative benefits, such as minimum compensation and healthcare subsidies, vehicle insurance, and sexual harassment policies.

The ballot initiative was largely funded by Uber, DoorDash and Lyft.

Prop 23: Authorizes State Regulation of Kidney Dialysis Clinics. Establishes Minimum Staffing and Other Requirements

This ballot initiative would require at least one licensed physician on site during treatment at outpatient kidney dialysis clinics.

Clinics would also be required to report data on dialysis-related infections to the state health department, as well as obtain consent from the same department before closing.

Additionally, Proposition 23 would prohibit clinics from discriminating against patients based on the source of payment for care.

State officials estimate that the measure would likely increase dialysis costs, resulting in increased state and local health care costs by tens of millions of dollars each year.

Ed. Note: The full text for all of the ballot measures can be read here.

KHTS FM 98.1 and AM 1220 is Santa Claritas only local radio station. KHTS mixes in a combination of news, traffic, sports, and features along with your favorite adult contemporary hits. Santa Clarita news and features are delivered throughout the day over our airwaves, on our website and through a variety of social media platforms. Our KHTS national award-winning daily news briefs are now read daily by 34,000+ residents. A vibrant member of the Santa Clarita community, the KHTS broadcast signal reaches all of the Santa Clarita Valley and parts of the high desert communities located in the Antelope Valley. The station streams its talk shows over the web, reaching a potentially worldwide audience. Follow @KHTSRadio on Facebook, Twitter, and Instagram.

More here:
What's On The Ballot? A Summary Of The 12 State Propositions For November 2020 Election - KHTS Radio

Covid-19 Impact on Global Adipose Derived Stem Cell Therapy Market Strategies, Comparison, Shares, Demand, Supply, Challenges and Forecast to 2026 -…

The report on Adipose Derived Stem Cell Therapy, gives an in-depth analysis of Global Adipose Derived Stem Cell Therapy Market based on aspects that are very important for the market study. Factors like production, market share, revenue rate, regions and key players define a market study start to end. This report gives an overview of market valued in the year 2019 and its growth in the coming years till 2026. The report is based on the in-depth view of Adipose Derived Stem Cell Therapy industry on the basis of market growth, market size, development plans and opportunities offered by the global Adipose Derived Stem Cell Therapy market. The energetic aspects studied in this report include SWOT analysis, feasibility and forecast information.

Request a sample of Adipose Derived Stem Cell Therapy Market report @ https://www.orbispharmareports.com/sample-request/42190

For the consumers to gain the in-depth analysis of the global Adipose Derived Stem Cell Therapy market and further growth of the market, the report offers significant statistics and information. Adipose Derived Stem Cell Therapy report studies the current state of the market to analyze the future opportunities and risks. Adipose Derived Stem Cell Therapy report provides a 360-degree global market state. Primarily, the report delivers Adipose Derived Stem Cell Therapy introduction, overview, market objectives, market definition, scope, and market size valuation.

Major companies of this report:

AlloCure Mesoblast Cellleris Antria Intrexon Celgene Corporation Tissue Genesis Cytori Therapeutics Corestem Pluristem Therapeutics Cyagen BioRestorative Therapies Lonza Pluristem Therapeutics Celltex Therapeutics Corporation iXCells Biotechnologies

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/42190

Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players. This Adipose Derived Stem Cell Therapy report also provides the readers with detailed figures at which the Adipose Derived Stem Cell Therapy market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the Adipose Derived Stem Cell Therapy is expected to mount and major factors driving markets growth. The study on global Adipose Derived Stem Cell Therapy market, offers deep insights about the Adipose Derived Stem Cell Therapy market covering all the crucial aspects of the market.

Adipose Derived Stem Cell Therapy Market Segmentation by Type:

Autologous Stem Cells Allogeneic Stem Cells

Adipose Derived Stem Cell Therapy Market Segmentation by Application:

Therapeutic Application Research Application

In addition, the report include deep dive analysis of the market, which is one of the most important features of the market. Furthermore, the need for making an impact is likely to boost the demand for the experts which are working in the market. Moreover, an in depth analysis of the competitors is also done to have an estimate for the market. The Adipose Derived Stem Cell Therapy market has its impact all over the globe. On global level Adipose Derived Stem Cell Therapy industry is segmented on the basis of product type, applications, and regions. It also focusses on market dynamics, Adipose Derived Stem Cell Therapy growth drivers, developing market segments and the market growth curve is offered based on past, present and future market data. The industry plans, news, and policies are presented at a global and regional level.

Place a purchase order of this report @ https://www.orbispharmareports.com/buy-now/42190

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

View post:
Covid-19 Impact on Global Adipose Derived Stem Cell Therapy Market Strategies, Comparison, Shares, Demand, Supply, Challenges and Forecast to 2026 -...

Ozzy Osbourne: I was convinced I was dying during nightmare health year – Kokomo Perspective

Ozzy Osbourne was "convinced" he was dying amid his year plagued with health setbacks.

The 'Crazy Train' hitmaker suffered a nightmare year in 2019 which saw him endure several medical issues including a fall, neck surgery, an infection in his hand, and hospitalization for the flu.

And at the start of 2020, he revealed he had been diagnosed with Parkinson's - which is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination - for which he later had stem cell treatment to try and ease the symptoms.

Discussing his year of ill health, Ozzy said: "I'm not back to 100 percent. I'm about 75 percent there, but it's such a slow recovery. Spine surgery is bad news, man. I've been in such a bad state with pain; I'm still having a lot of pain.

"There was a point I was convinced that I was dying. I was in that much discomfort and pain and misery. I thought they were all hiding it from me. I remember saying to Sharon, 'You've gotta level with me. Is it worse than you're making it out [to be]?' She says, 'No.' ... I've dropped all the medication for pain now."

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free. Please support us by making a contribution.

And despite his health woes, the 71-year-old rocker is itching to get back on stage as soon as the coronavirus pandemic - which has forced all concerts to be cancelled - has passed.

He added in an interview for SiriusXM: "I cannot wait [to get on stage], but I was talking to Tony Iommi the other day, and he was saying with the way it's going with this coronavirus, indoor shows will be a thing of the past."

Meanwhile, Ozzy's daughter Kelly Osbourne said earlier this year her dad is beginning to feel much better, following a "treatment of stem cell".

She explained: "Seeing after one treatment of stem cell what has happened and the progress that he's made is mind blowing. He wants to get up. He wants to do things. He wants to be part of the world again. He's walking better. He's talking better. His symptoms are lessening. He is building the muscle strength back that he needs after his spine surgery."

Follow this link:
Ozzy Osbourne: I was convinced I was dying during nightmare health year - Kokomo Perspective

BioMarin (BMRN) to Report Q2 Earnings: What’s in the Cards? – Yahoo Finance

BioMarin Pharmaceutical BMRN is set to report second-quarter 2020 results on Aug 4, after market close. In the last reported quarter, the company delivered an earnings surprise of 90.91%.

BioMarins shares have risen 43.9% this year so far, outperforming the industrys increase of 5%.

The companys earnings performance has been mixed. Its earnings beat expectations in three of the last four quarters and missed in one, with the surprise being 22.34%, on average.

BioMarin Pharmaceutical Inc. Price and EPS Surprise

BioMarin Pharmaceutical Inc. price-eps-surprise | BioMarin Pharmaceutical Inc. Quote

The negative impact of disruptions of day-to-day operations of clinics and hospitals is expected to have been more acute in the second quarter than the first. The pandemic is expected to have caused demand interruptions such as missed patient infusions and disruption in new patient starts of some of BioMarins drugs in the second quarter.

Sales of Kuvan are likely to have been driven by patient growth in North America. However, Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil. Sales of both the drugs had increased in the first quarter. It remains to be seen if the trend has reversed in the second quarter. The respective Zacks Consensus Estimate for Kuvan, Naglazyme and Vimzim is $114 million, $86 million and $119 million.

In new medicine, Palynziq injection, a seasonal slowing of new patient enrollments and patient starts had hurt sales in the first quarter. It remains to be seen if the trend reversed in the second quarter. The Zacks Consensus Estimate for Palynziq is $35.4 million.

We expect management to provide a thorough update on its pipeline. BioMarins regulatory applications for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, are under review in the United States (PDUFA Date: Aug 21) and Europe with potential approval and launch in the United States in the second half of 2020.

Another important candidate in its pipeline is vosoritide, which has been developed to treat achondroplasia, the most common form of dwarfism. The company filed a regulatory application for vosoritide in the EU in July and expects to file the same in the United States in the third quarter of 2020.

Meanwhile, investors will also look for any changes to its financial guidance for 2020 on the second-quarter conference call.

Our proven model does not conclusively predict an earnings beat for BioMarin this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.

Earnings ESP: Its Earnings ESP is 0.00% as both the Zacks Consensus Estimate as well as the Most Accurate Estimate is pegged at 16 cents per share. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Story continues

See the rest here:
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards? - Yahoo Finance

Cell and Gene Therapy Market Size to Reach over $14 Billion by 2025 – Arizton – PRNewswire

CHICAGO, July 30, 2020 /PRNewswire/ -- The global cell and gene therapy market is expected to grow at a CAGR of over 30% during the period 20192025.

Key Highlights Offered in the Report:

Key Offerings:

Get your sample today! https://www.arizton.com/market-reports/cell-and-gene-therapy-market

Cell and Gene Therapy Market Segmentation

Cell and Gene Therapy Market by Product

Cell and Gene Therapy Market by Disease

Cell and Gene Therapy Market by End-user

Cell and Gene Therapy Market Dynamics

Cell & gene therapies are emerging as the most dynamic field in medicine with a lot of ongoing R&D. Various components under cell & gene therapy such as injectable-based cell therapy, tissue-based products, vector-based gene therapy, and cell-based immunotherapy are witnessing cutting edge research to advance the clinical indications for these products. Vendors are actively conducting clinical trials to gain regulatory approval in different countries and regions with huge untapped potential.

Key Drivers and Trends fueling Market Growth:

Cell and Gene Therapy Market Geography

North America dominated the market and plays an important role in the adoption of cell & gene therapies. However, the initial product development and approvals started in China, Japan, and Europe. Post the approval of medicines in the US in 2017, the market in North America witnessed faster growth, and funds across the globe started flowing into clinical trials in the region. Many vendors started acquiring smaller companies to enter the North American region.

Get your sample today! https://www.arizton.com/market-reports/cell-and-gene-therapy-market

Cell and Gene Therapy Market by Geography

Prominent Vendors

Other Prominent Vendors

Explore our healthcare & lifesciences profileto know more about the industry.

Read some of the top-selling reports:

About Arizton:

AriztonAdvisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Mail:[emailprotected] Call:+1-312-235-2040 +1-302-469-0707

SOURCE Arizton Advisory & Intelligence

Here is the original post:
Cell and Gene Therapy Market Size to Reach over $14 Billion by 2025 - Arizton - PRNewswire

Meso Numismatics Update on 2nd Transaction with Global Stem Cells – GlobeNewswire

July 31, 2020 15:58 ET | Source: Meso Numismatics, Inc.

LAS VEGAS, NV, July 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has recently successfully made the second payment ($75,000) to Global Stem Cells Group on time as per the companys LOI amendment dated April 22, 2020.

We are excited about the pending acquisition of Global Stem Cells Group, said David Christensen, CEO and President of Meso Numismatics, Inc. We are extremely optimistic about the opportunities that Stem Cell Biotechnology and the future that Regenerative Medicine can offer the world.

This press release should be read in conjunction with the all other filings on http://www.sec.gov

For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company's breadth of business experience and technology team, the Company will continue to help companies grow.

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words plan, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact: Investor.relations@mssvinc.com Telephone: (800) 956-3935

Read the original:
Meso Numismatics Update on 2nd Transaction with Global Stem Cells - GlobeNewswire

Cancer Therapy Market Projected Growth Rate 2020 | Demand Status, Future Scope, Upcoming Trends of Manufacturers, Global Share with Industry Size…

Pfizer Inc.

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999546

Key Market Trends:

The Target Therapy Segment is Expected to show the Fastest Growth in the Forecast Period

The target therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells.

The breast cancer segment is belived to account for the largest market size over the forecast period. This is majorly attrobuted to the higher and continuously increaisng prevalence of breast cancer acoss the world. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer.

North America Currently Dominates the Cancer Therapy Market and is Expected to Continue in the Forecast Period

North America currently dominates the market for cancer therapy and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of cancer therapy. The United States holds majority of the market in the North American region, due to the rising prevalence of cancer in the country. According to the National Cancer Institute (NCI), in 2016, 1.6 million people suffered from cancer, and around 0.5 million people died from cancer. This figure indicates that the prevalence of cancer is rapidly increasing in the United States.

The Report Covers:

Purchase this Report (Price 4500 USD for single user license) https://www.industryresearch.co/purchase/13999546

Detailed TOC of Cancer Therapy Market Report 2020-2024:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increasing Patient Assistance Programs (PAPs) 4.2.2 Growing Government Initiatives for Cancer Awareness 4.2.3 Rising Prevalence of Cancer Worldwide 4.2.4 Strong R&D Initiatives from Key Players 4.3 Market Restraints 4.3.1 Fluctuation in Reimbursement Policies 4.3.2 High Cost of Cancer Therapies 4.4 Porters Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Treatment Type 5.1.1 Chemotherapy 5.1.2 Targeted Therapy 5.1.3 Immunotherapy 5.1.4 Hormonal Therapy 5.1.5 Other Treatment Types 5.2 By Cancer Type 5.2.1 Blood Cancer 5.2.2 Breast Cancer 5.2.3 Prostate Cancer 5.2.4 Gastrointestinal Cancer 5.2.5 Gynecologic Cancer 5.2.6 Respiratory/Lung Cancer 5.2.7 Other Cancer Types 5.3 By End User 5.3.1 Hospitals 5.3.2 Spcialty Clinics 5.3.3 Cancer and Radiation Therapy Centers 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 South Korea 5.4.3.5 Australia 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Amgen Inc. 6.1.2 AstraZeneca PLC 6.1.3 Bayer AG 6.1.4 Johnson and Johnson 6.1.5 Merck & Co. Inc. 6.1.6 F. Hoffmann-La Roche AG 6.1.7 Eli Lilly and Company 6.1.8 Novartis AG 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Thyme Extract Market 2020 Industry Outlook by Business Share, Industry Price Trend, Size Estimation, Latest Research Report by Business Analysis and Forecast Research till 2025

Electronic Spirometer Market Size and Share 2020 Global Growth Rate Analysis by Industry Insights, Future Trends, Revenue, and Demand Status with COVID-19 Analysis Forecast till 2025

Immune Thrombocytopenia Market Size 2020-2026 Production, Sales and Consumption Status and Prospects Professional Market Research, COVID-19 Analycic

Pathogen Testing Market 2020 Global Growth Rate Analysis by Industry Size and Share, Future Trends, Revenue, and Demand Status with COVID-19 Analysis Forecast till 2025

Pathological Examination Market Growth Rate by Share 2020-2026 | Revenue Forecast by Product Type, Applications and Regions and COVID-19 impact on Global Industry

Composite Coil Springs Market 2020: Top Coverage of Key Companies with Size and Share, Expected Growth Analysis with Revenue, Future Trends and Technology Forecast by 2026

Continued here:
Cancer Therapy Market Projected Growth Rate 2020 | Demand Status, Future Scope, Upcoming Trends of Manufacturers, Global Share with Industry Size...

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with…

July 31, 2020 15:38 ET | Source: Genmab A/S

Company Announcement

Copenhagen, Denmark; July 31, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Myeloma Network (EMN) in collaboration with Janssen Research & Development, LLC (Janssen) reported positive results from the Phase 3 APOLLO (MMY3013) study of the subcutaneous (SC) formulation of daratumumab in combination with pomalidomide and dexamethasone (Pd) versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide (an immunomodulatory drug) and a proteasome inhibitor (PI). The study met the primary endpoint of improving progression-free survival (PFS). Overall, the safety profile of daratumumab SC in combination with Pd was consistent with the safety profile for each therapy separately.

We are pleased with these positive results for daratumumab, administered as a subcutaneous formulation, in combination with pomalidomide and dexamethasone. The corresponding intravenous regimen was previously approved by the U.S. FDA based on the Phase1 single-arm EQUULEUS study, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Janssen Biotech, Inc., which obtained an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab in 2012, intends to discuss the data with health authorities in preparation for regulatory submissions and plans to submit the data for presentation at an upcoming medical conference.

The APOLLO study was designed to confirm the results from the Phase 1 EQUULEUS (MMY1001) study, which investigated intravenous (IV) daratumumab plus Pd in the same indication. In June 2017, the U.S. Food and Drug Administration (U.S. FDA) approved the use of DARZALEX in combination with Pd for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and aPI based on the results of the EQUULEUS study.

About the APOLLO (MMY3013) study This Phase 3 (NCT03180736), randomized, open-label, multicenter study included 304 patients with multiple myeloma who have previously been treated with lenalidomide and a PI. Patients were randomized 1:1 to either receive daratumumab in combination with Pd or Pd alone. In the original design of the study, patients in the daratumumab plus Pd arm were treated with the IV formulation of daratumumab. As of Amendment 1, all new subjects in the experimental arm were dosed with the SC formulation of daratumumab and patients who had already begun treatment with IV daratumumab had the option to switch to the SC formulation. The primary endpoint of the study was PFS. The study was conducted in Europe under an agreement between Janssen, EMN and Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON).

About multiple myelomaMultiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma.2 Approximately 26,000 new patients were estimated diagnosed with multiple myeloma and approximately 13,650 people were expected to have died from the disease in the U.S. in 2018.3 Globally, it was estimated that 160,000 people were diagnosed and 106,000 died from the disease in 2018.4 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.5

About DARZALEX(daratumumab) DARZALEX (daratumumab) intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy7. Daratumumab is the first subcutaneous CD38-directed antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S.

In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.8 DARZALEX FASPRO is the first subcutaneous CD38-directed antibody approved in the U.S. for the treatment of multiple myeloma.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).6,9,10,11,12

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations: Andrew Carlsen, Senior Director, Investor Relations T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody. Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX and DARZALEX FASPRO are trademarks of Janssen Pharmaceutica NV. TEPEZZA is a trademark of Horizon Therapeutics plc.

1 American Cancer Society. "Multiple Myeloma Overview." Available at http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma.Accessed June 2016. 2 National Cancer Institute. "A Snapshot of Myeloma." Available at http://www.cancer.gov/research/progress/snapshots/myeloma. Accessed June 2016. 3 Globocan 2018. United States of America Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/840-united-states-of-america-fact-sheets.pdf. 4 Globocan 2018. World Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed December 2018. 5 American Cancer Society. "How is Multiple Myeloma Diagnosed?" http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-diagnosis. Accessed June 2016 6 DARZALEX Prescribing information, September 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s024lbl.pdf Last accessed September 2019 7 DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed June 2020 8 DARZALEX FASPRO Prescribing information, May 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf Last accessed May 2020 9 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848. 10 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21. 11 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94. 12 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.Blood. 2012; 120(21): abstract 2974.

Company Announcement no. 33 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark

See the original post:
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with...

BMT survivor study finds significant breast cancer risk in young women who received total body irradiation – The Mix

Women who had total body irradiation to prepare for blood or marrow transplantation before age 30 had a 4.5-fold increase in their risk of developing breast cancer later in life.

Smita Bhatia, M.D.A new study examining long-term outcomes of blood or marrow transplantation (BMT) found that patients who received total body irradiation (TBI) at age 30 or younger had a 4.5-fold increase in their risk of developing breast cancer later in life compared with the general population. The research, published in the Journal of Clinical Oncology on July 16, 2020, also found increased risk of breast cancer among women exposed to alkylating agents and anthracyclines as part of BMT.

Women who received TBI were at a 1.5-fold higher risk of breast cancer when compared with the general population overall and at a 4.5-fold higher risk when the exposure occurred at age 30 years or younger, the authors write. Women who were exposed to TBI before age 30 had a 13.9 percent risk of being diagnosed with breast cancer by age 50, they found. By comparison, the average American woman has a 2.38 percent risk of being diagnosed with breast cancer at age 50, according to the American Cancer Society.

As a result of this study, we will be recommending that those transplanted at ages less than 30 years with TBI receive screening with mammography and breast MRI for early detection of breast cancer, said Smita Bhatia, M.D., senior author of the study and director of the Institute for Cancer Outcomes and Survivorship and a senior scientist in the ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham.

"We plan to further study how different aspects of TBI dose and delivery technique are related to secondary cancers, said Andrew McDonald, M.D., assistant professor in the Department of Radiation Oncology and first author of the study. Our long-term goal is to improvetreatment techniques for future patients undergoing BMT as part of their cancer care."

This research was based on the BMT Survivor Study, which is enrolling more than 10,000 patients from the UAB, City of Hope and the University of Minnesota medical centers who underwent transplantation between 1974 and 2014 and survived for at least two years. Survival rates after BMT have been improving at the rate of 10 percent per decade, Bhatia said. But these BMT survivors are uniquely vulnerable to long-term health problems, she said.

Some 23,000 patients received BMT in the United States in 2018, according to the latest figures from the Center for International Blood & Marrow Transplant Research. These are mainly patients with blood cancers such as leukemia, myeloma or lymphoma that are progressing or who have a high risk of relapse. Total body irradiation and chemotherapeutic exposures such as alkylating agents and anthracyclines are used to prepare the patient for BMT.

About 50 percent of [BMT] transplant patients overall receive total body irradiation, including a higher proportion of those patients who are younger, Bhatia said. The decision whether or not to use TBI as part of BMT is based on the primary cancer that is being treated and the type of transplant that is performed, she noted. TBI is used more often among those who receive transplants from their siblings or unrelated donors known as allogeneic transplant as compared to when they receive transplants from their own stem cells, known as autologous transplant.

Bhatias institute is particularly interested in identifying predictive traits of cancer survivors at higher risk for long-term problems that could enable health care providers to tailor screenings and other interventions to these populations.

One under-studied outcome in BMT survivors is the magnitude of risk of breast cancer among women treated with TBI across all ages, Bhatia said. Early detection is known to improve breast-cancer outcomes and data on the women at highest risk to develop radiation-related breast cancer would allow health providers to screen these women at earlier ages.

Women who had a history of breast cancer before BMT, chest radiation before BMT or a mastectomy before BMT were not included in the study cohort. The researchers studied a total of 1,464 female BMT survivors 788 who had allogeneic transplants and 676 who had autologous transplants. TBI was used in 46 percent (660) of these patients. The median length of follow-up was 9.3 years. The most common diagnoses were acute myeloid leukemia or myelodysplastic syndrome (27.5 percent), non-Hodgkin lymphoma (23.3 percent), plasma cell dyscrasias (18 percent), and chronic myelogenous leukemia (10.3 percent).

Thirty-seven of the women developed breast cancer during the study period 19 of the women who had allogeneic transplants and 18 who had autologous transplants. The women developed breast cancer at a median of 9.1 years after BMT. Breast cancers, inclusive of ductal carcinoma in situ, were identified from the completed BMTSS survey.

"To our knowledge, this is the first report of an increased risk of subsequent breast cancer after TBI among female autologous BMT survivors, the authors write. The observation that exposure to alkylating agents and anthracyclines is associated with an increased risk of subsequent breast cancer has been noted in long-term outcomes studies of childhood cancer survivors; however, to our knowledge, this is the first report of this association among BMT survivors.

The researchers did not observe a relationship between TBI dose and the risk of subsequent breast cancer in this study, they write. But the distribution of TBI doses used for the women included in this study was narrow, and additional research is needed to determine if a dose-response relationship between TBI and subsequent breast cancer exists.

In addition to McDonald and Bhatia, other authors of Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report, include Yanjun Chen, Jessica Wu, Lindsey Hageman, Liton Francisco, Michelle Kung, Emily Ness, Wendy Landier, Ph.D., Kevin Battles, and Donna Salzman, M.D., of UAB; F. Lennie Wong, Ph.D., Saro H. Armenian, D.O., and Stephen J. Forman, M.D., of City of Hope; and Daniel J. Weisdorf, M.D., and Mukta Arora, M.D., of the University of Minnesota.

The work was supported in part by grants from the National Cancer Institute (R01 CA078938 and U01 CA213140) and the Leukemia Lymphoma Society (R650216).

See original here:
BMT survivor study finds significant breast cancer risk in young women who received total body irradiation - The Mix

Personalized Cell Therapies Market Trends, Outlook, and Opportunity Analysis up to 2021 focuses on major key players PCT Cell Therapy Services, LLC…

The latest fundamental insights on Personalized Cell Therapies Market with COVID-19 Industry Impact, Forecast Development Scope, and Growth Prospects 2021-2026 is released by PBI. Every market driver, Personalized Cell Therapies marketing channel, growth-driving segments, risk analysis & mitigation is given in this report. The dynamic effects on worldwide Personalized Cell Therapies economies and crucial primary & secondary data sources offered in this study. The Personalized Cell Therapies Industry competitive landscape, regional analysis, future patterns, Top companies, current development rate, & gross margin status is provided.

The Personalized Cell Therapies Industry landscape view, demand, revenue, market share & pricing structure analysis is offered. The changing Industry dynamics, plans, CAGR, COVID-19 impact on consumer demand, availability of raw materials is analyzed completely. The market development rate during 2020-2025 with past & present industry performance is assessed in this report.

Get Sample Report Copy (Including TOC, portrayal, tables and graphs) Here: https://www.precisionbusinessinsights.com/request-sample?product_id=17290

The top companies & competitive landscape study is as follows:

PCT Cell Therapy Services, LLC (U.S),S. Stem Cell, Inc. (U.S),Bellicum Pharmaceuticals, Inc. (U.S),Saneron CCEL Therapeutics, Inc. (U.S),StemGenex (U.S),Vericel Corporation.(U.S)

By Cell Type

Market Analysis By Regions

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Request to customize @ https://www.precisionbusinessinsights.com/request-customisation?product_id=17290

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Personalized Cell Therapies Market Overview

Personalized Cell Therapies Supply Chain Analysis

Personalized Cell Therapies Pricing Analysis

Global Personalized Cell Therapies Market Analysis and Forecast by Type

Global Personalized Cell Therapies Market Analysis and Forecast by Application

Global Personalized Cell Therapies Market Analysis and Forecast by Sales Channel

Global Personalized Cell Therapies Market Analysis and Forecast by Region

North America Personalized Cell Therapies Market Analysis and Forecast

Latin America Personalized Cell Therapies Market Analysis and Forecast

Europe Personalized Cell Therapies Market Analysis and Forecast

Asia Pacific Personalized Cell Therapies Market Analysis and Forecast

Middle East & Africa Personalized Cell Therapies Market Analysis and Forecast

Competition Landscape

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

See original here:
Personalized Cell Therapies Market Trends, Outlook, and Opportunity Analysis up to 2021 focuses on major key players PCT Cell Therapy Services, LLC...